TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31439037
Drug: MEDI0680 administered
Normalized name: MEDI0680
DrugBank: MEDI0680 (DB15768)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MEDI0680 administered intravenously at doses of 0.1, 0.5, 2.5, 10, or 20 mg/kg Q2W or Q3W, with some cohorts receiving 20 mg/kg once a week for 2 or 4 weeks, then 20 mg/kg Q2W for a total treatment duration of 12 months or until progression.
Study: 31439537
Drug: Carfilzomib at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carfilzomib at a dose of 20 mg/m²
Study: 31440722
Drug: Lacosamide (adjunctive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lacosamide (adjunctive therapy)
Study: 31440722
Drug: Lacosamide (adjunctive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lacosamide (adjunctive therapy) in SCB (+) subgroup (n=149)
Study: 31440722
Drug: Lacosamide (adjunctive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lacosamide (adjunctive therapy) in SCB (-) subgroup (n=153)
Study: 31440946
Drug: Pasireotide (subcutaneous)
DrugBank: Pasireotide (DB06663)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pasireotide (subcutaneous)
Study: 31442103
Drug: T-DM1 at
Normalized name: T-DM1
DrugBank: Trastuzumab emtansine (DB05773)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: T-DM1 at 3.6 mg/kg intravenously every 3 weeks plus neratinib at 120, 160, 200, or 240 mg/d orally
Study: 31442103
Drug: T-DM1 at
Normalized name: T-DM1
DrugBank: Trastuzumab emtansine (DB05773)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: T-DM1 at 3.6 mg/kg intravenously every 3 weeks plus neratinib at 160 mg/d orally
Study: 31442103
Drug: T-DM1 at
Normalized name: T-DM1
DrugBank: Trastuzumab emtansine (DB05773)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: T-DM1 at 3.6 mg/kg intravenously every 3 weeks plus neratinib (various doses)
Study: 31442327
Drug: Radium-223 re-treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radium-223 re-treatment (up to 6 additional injections)
Study: 31442817
Drug: Pembrolizumab (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab (200 mg IV every 3 weeks) + Metronomic cyclophosphamide (50 mg b.i.d. one week on and one week off)
Study: 31443741
Drug: Samalizumab (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Samalizumab (50 to 600 mg/m)
Study: 31444088
Drug: Pre-treatment pain
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-treatment pain and dyspnea
Study: 31581055
Drug: Nivolumab 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab 3 mg/kg every 2 weeks for up to 2 years
Study: 31446142
Drug: Self-administered electronic
Normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-administered electronic screening for SUD risk, depression and anxiety using TAPS and AOQ measures
Study: 31446511
Drug: Apalutamide 240
Normalized name: apalutamide 240 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apalutamide 240 mg once-daily for 1 week, followed by continuous daily dosing (4 weeks/cycle)
Study: 31446987
Drug: Rovalpituzumab tesirine
Normalized name: Rovalpituzumab tesirine
DrugBank: Rovalpituzumab tesirine (DB13017)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rovalpituzumab tesirine (Rova-T) 0.2 or 0.3 mg/kg by intravenous infusion on Day 1 of each 6-week cycle for 2 doses and dexamethasone (8 mg BID oral) on D-1, D1, and D2 of each 6-week cycle
Study: 31448107
Drug: Home-based exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Home-based exercise program after total hip arthroplasty, details on dosage and duration not available.
Study: 31448214
Drug: Intensity-modulated radiation
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensity-modulated radiation therapy (IMRT) with a prescription dose of 68.1 Gy in 30 fractions
Study: 31449522
Drug: Antibiotic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic treatment for Buruli ulcer
Study: 31450823
Drug: Anti-inflammatory therapy
Normalized name: Surpass Anti-Inflammatory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-inflammatory therapy (CANTOS Trial, NCT01327846)
Study: 31451367
Drug: Bevacizumab with
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab with first-line chemotherapy (capecitabine/oxaliplatin)
Study: 31451367
Drug: Bevacizumab with
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab with capecitabine-based chemotherapy vs fluorouracil-based regimens
Study: 31451445
Drug: Blinatumomab, 60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blinatumomab, 60 µg/m²
Study: 31452586
Drug: Hyperglycemia (blood
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperglycemia (blood glucose level ≥ 169 mg/dL)
Study: 31452586
Drug: Lower blood
Normalized name: dragon's blood extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower blood glucose level (<169 mg/dL)
Study: 31452902
Drug: Once-daily tacrolimus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily tacrolimus dosing
Study: 31452902
Drug: Twice-daily tacrolimus
Normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Twice-daily tacrolimus dosing
Study: 31453428
Drug: Monthly mailed
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Monthly mailed healthy lifestyle intervention toolkit
Study: 31455681
Drug: Mogamulizumab (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mogamulizumab (0.3 or 1.0 mg/kg) and Nivolumab (3.0 mg/kg)
Study: 31455712
Drug: Daily supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily supplementation with 1200 mg of elemental calcium during pregnancy and lactation
Study: 31455851
Drug: Obinutuzumab plus
Normalized name: Obinutuzumab
DrugBank: Obinutuzumab (DB08935)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Obinutuzumab plus fludarabine and cyclophosphamide (G-FC)
Study: 31456142
Drug: ONC201 (administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: ONC201 (administered orally once every week)
Study: 31456261
Drug: Plerixafor 0.32
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plerixafor 0.32 mg/kg and bortezomib 1.3 mg/m²
Study: 31456261
Drug: Plerixafor in
Normalized name: plerixafor Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plerixafor in combination with bortezomib
Study: 31462437
Drug: Antibiotic use
Normalized name: Antibiotics for systemic use
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic use in patients with viraemia
Study: 31463078
Drug: Heavy-slow resistance
Normalized name: Slow-Fe
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heavy-slow resistance training (HSR) combined with ultrasound-guided corticosteroid injection
Study: 31463362
Drug: Higher injection
Normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher injection pressure (550 pound/inch)
Study: 31463362
Drug: Lower injection
Normalized name: flowers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower injection pressure
Study: 31463362
Drug: Higher injection
Normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher injection pressure
Study: 31467699
Drug: 1200 mg
Normalized name: aspirin 1200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1200 mg of protein hydrolysate from Coldwater Shrimp
Study: 31469058
Drug: Pressurized intraperitoneal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pressurized intraperitoneal aerosol chemotherapy (PIPAC) with cisplatin/doxorubicin administered during standard laparoscopy
Study: 31470902
Drug: Obinutuzumab (Gazyvaro)
Normalized name: Obinutuzumab
DrugBank: Obinutuzumab (DB08935)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Obinutuzumab (Gazyvaro) combined with low-dose radiotherapy (LDRT)
Study: 31471313
Drug: Regorafenib 120
Normalized name: Regorafenib
DrugBank: Regorafenib (DB08896)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Regorafenib 120 mg/day
Study: 31471313
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of sunitinib and regorafenib
Study: 31471312
Drug: GSK2816126 (EZH2
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK2816126 (EZH2 inhibitor) at doses ranging from 50 to 3,000 mg twice weekly, given 3-weeks-on/1-week-off in 28-day cycles
Study: 31471376
Drug: Oral 5-azacytidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral 5-azacytidine (AZA) 300 mg daily on days 1 to 14 and romidepsin (ROMI) 14 mg/m2 on days 8, 15, and 22 on a 35-day cycle
Study: 31471376
Drug: Oral 5-azacytidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral 5-azacytidine (AZA) 100 mg daily on days 1 to 14 to 300 mg daily on days 1 to 21 and romidepsin (ROMI) 10 mg/m2 on days 8 and 15 to 14 mg/m2 on days 8, 15, and 22
Study: 31473727
Drug: Oral vitamin
Normalized name: vitamin A Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral vitamin D 4000 IU/day for 6 months
Study: 31473943
Drug: Quizartinib hydrochloride
Normalized name: quizartinib
DrugBank: Quizartinib (DB12874)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Quizartinib hydrochloride (initial dose 20/30 mg/day)
Study: 31474600
Drug: Conventional synthetic
Normalized name: Synthetic camphor
DrugBank: Synthetic camphor (DB14156)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional synthetic disease-modifying antirheumatic drugs and/or tumor necrosis factor inhibitors
Study: 31474848
Drug: Cognitive training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive training with concurrent anodal transcranial direct current stimulation (tDCS) over the left dorsolateral prefrontal cortex
Study: 31474848
Drug: Cognitive training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive training with concurrent anodal transcranial direct current stimulation (tDCS)
Study: 31475295
Drug: Sacubitril-valsartan treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sacubitril-valsartan treatment
Study: 31475856
Drug: hs-cTnl concentrations
Approvals — FDA: no, EMA: no, PMDA: no
Description: hs-cTnl concentrations <5 ng/L
Study: 31475856
Drug: hs-cTnl concentrations
Approvals — FDA: no, EMA: no, PMDA: no
Description: hs-cTnl concentrations <2 ng/L
Study: 31476851
Drug: Brentuximab Vedotin
Normalized name: Brentuximab Vedotin
DrugBank: Brentuximab vedotin (DB08870)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Brentuximab Vedotin (BV) administered intravenously at 1.8 mg/kg every 3 weeks
Study: 31477052
Drug: Next generation
Normalized name: Next Choice One Dose
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Next generation sequencing of the T cell receptor (TCR) repertoire
Study: 31477198
Drug: SSB intake
Approvals — FDA: no, EMA: no, PMDA: no
Description: SSB intake at 5 years of age (100 ml/d increments)
Study: 31477906
Drug: Low-affinity CD19
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-affinity CD19 CAR T cell therapy
Study: 31479702
Drug: Pembrolizumab with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab with local therapy (stereotactic radiosurgery, surgery, or laser interstitial thermal therapy)
Study: 31479702
Drug: Pembrolizumab without
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab without local therapy
Study: 31481121
Drug: Low-dose post-transplant
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose post-transplant cyclophosphamide (14.5 mg/kg on days 3 and 4) with anti-thymocyte globulin (ATG)
Study: 31481511
Drug: Galunisertib 150
Normalized name: SAPANISERTIB
DrugBank: Sapanisertib (DB11836)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Galunisertib 150 mg twice daily for 14 days on/14 days off
Study: 31481566
Drug: Antirheumatic treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antirheumatic treatments
Study: 31481566
Drug: Comorbidities and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comorbidities and prescribed drugs identification
Study: 31483485
Drug: sipuleucel-T immunotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: sipuleucel-T immunotherapy (3 biweekly infusions)
Study: 31483485
Drug: sipuleucel-T immunotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: sipuleucel-T immunotherapy
Study: 31485435
Drug: Various treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Various treatments for prostate cancer including novel therapies
Study: 31485982
Drug: Rectal cancer
Normalized name: Cancer/testis antigen 1
DrugBank: Cancer/testis antigen 1 (DB19291)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rectal cancer patients
Study: 31487564
Drug: Lipid lowering
Normalized name: Lipid lowering agent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lipid lowering therapy
Study: 31488093
Drug: rs10132552 TC + CC
Normalized name: TC-6987
DrugBank: TC-6987 (DB14854)
Approvals — FDA: no, EMA: no, PMDA: no
Description: rs10132552 TC + CC
Study: 31488216
Drug: HuMax-IL8 (BMS-986253)
Normalized name: Bms-986089 (fully human anti-myostatin adnectin)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HuMax-IL8 (BMS-986253) administered IV every 2 weeks at doses of 4, 8, 16, or 32 mg/kg
Study: 31488216
Drug: HuMax-IL8 (BMS-986253)
Normalized name: Bms-986089 (fully human anti-myostatin adnectin)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HuMax-IL8 (BMS-986253) administered IV every 2 weeks
Study: 31488227
Drug: RESOLVE plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: RESOLVE plus treatment as usual (TAU)
Study: 31488473
Drug: Self-reported preventive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-reported preventive measures and management strategies for knee symptoms (including non-pharmacological treatments and CAM)
Study: 31491604
Drug: Hormone receptor-positive
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormone receptor-positive and HER2-positive tumours
Study: 31492778
Drug: Antidepression or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidepression or antianxiety treatment among patients with ACS who received treatment after PCI.
Study: 31492795
Drug: Concurrent use
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent use of ≥2 CNSDs
Study: 31493051
Drug: Clean Control
Normalized name: ALUMINUM ZIRCONIUM TETRACHLOROHYDREX GLY 0.2 g in 1 g TOPICAL STICK [Mitchum Clinical Soft Solid Clean Control]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clean Control (CC) group
Study: 31494181
Drug: FOLFIRINOX ×
Approvals — FDA: no, EMA: no, PMDA: no
Description: FOLFIRINOX × 6 cycles, followed by radiation therapy (50 Gy in 25 fractions) concurrent with fixed-dose rate gemcitabine (1 g/m2)
Study: 31495595
Drug: MenACWY-CRM booster
Approvals — FDA: no, EMA: no, PMDA: no
Description: MenACWY-CRM booster dose
Study: 31496644
Drug: 0.01 mL
Normalized name: menthol 0.01 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.01 mL (40 μg) intravitreal dexamethasone solution
Study: 31496644
Drug: 0.03 mL
Normalized name: polyvinyl alcohol 0.03 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.03 mL (120 μg) intravitreal dexamethasone solution
Study: 31496644
Drug: 0.05 mL
Normalized name: xenon 0.05 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.05 mL (200 μg) intravitreal dexamethasone solution
Study: 31496644
Drug: Intravitreal dexamethasone
Normalized name: Dexamethasone Intravitreal Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal dexamethasone solution
Study: 31498564
Drug: Osimertinib 80
Normalized name: osimertinib 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Osimertinib 80 mg once daily (D3-32)
Study: 31498564
Drug: Simvastatin 40
Normalized name: simvastatin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin 40 mg single oral doses (D1 and D31)
Study: 31499518
Drug: PrEP first
Normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PrEP first discontinuation
Study: 31499518
Drug: PrEP final
Normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PrEP final discontinuation
Study: 31500586
Drug: Cetuximab in
Normalized name: cetuximab Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cetuximab in combination with irinotecan and fluorouracil
Study: 31501123
Drug: Analgesic medication
Normalized name: ANALGESIC CREAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Analgesic medication use
Study: 31501132
Drug: Daily screening
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily screening for readiness to discontinue MV
Study: 31501132
Drug: Modes of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modes of MV used before initial discontinuation attempts
Study: 31501132
Drug: Sedation and
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sedation and mobilisation practices to facilitate weaning and discontinuation
Study: 31501975
Drug: Botulinum neurotoxin
Normalized name: Botulinum neurotoxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botulinum neurotoxin type A (BoNT-A) treatment
Study: 31502117
Drug: Aprutumab ixadotin
Normalized name: Anvatabart opadotin
DrugBank: Anvatabart opadotin (DB18290)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aprutumab ixadotin (0.1-1.3 mg/kg, administered intravenously on day 1 of every 21-day cycle)
Study: 31502400
Drug: Cediranib at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cediranib at the pediatric maximum tolerated dose of 12 mg/m²
Study: 31502421
Drug: Mepolizumab SC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mepolizumab SC 40 mg (bodyweight <40 kg) or 100 mg (≥40 kg) every 4 weeks for 12 weeks
Study: 31502421
Drug: Mepolizumab SC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mepolizumab SC 40 mg or 100 mg
Study: 31504335
Drug: CMV viremia
Normalized name: CMV-immune globulin
DrugBank: Human cytomegalovirus immune globulin (DB13886)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CMV viremia (detected CMV DNA, median plasma viral load 498 IU/mL, IQR 259-2390)
Study: 31504342
Drug: Depot Medroxyprogesterone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Depot Medroxyprogesterone Acetate (DMPA) 150 mg intramuscular injection
Study: 31506080
Drug: Novel FSHD
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Novel FSHD functional composite COA made up of 18 evaluator-administered motor tasks in the domains of shoulder/arm, hand, core/abdominal, leg, and balance function
Study: 31506080
Drug: Orofacial strength
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orofacial strength using the Iowa Oral Performance Instrument
Study: 31506385
Drug: Dabrafenib (specific
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dabrafenib (specific dosage and duration not provided)
Study: 31506387
Drug: Rovalpituzumab tesirine
Normalized name: Rovalpituzumab tesirine
DrugBank: Rovalpituzumab tesirine (DB13017)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rovalpituzumab tesirine (Rova-T) 0.3 mg/kg once every 6 weeks for two cycles
Study: 31507322
Drug: Other Atypical
Normalized name: Ether
DrugBank: Diethyl ether (DB13598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other Atypical Antipsychotics (AAPs)
Study: 31508232
Drug: Oral health
Normalized name: CETYLPYRIDINIUM CHLORIDE 0.07 g in 100 mL ORAL RINSE [Assured Oral Health Fresh Mint]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral health education intervention (three educational sessions over a six-week period)
Study: 31508518
Drug: Ibrutinib (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibrutinib (50 mg/kg p.o daily for three weeks)
Study: 31512728
Drug: iscalimab (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: iscalimab (10 mg/kg intravenously over 12 weeks)
Study: 31513018
Drug: Chemoimmunotherapy (CIT)
Normalized name: Cit
DrugBank: Citrulline (DB00155)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chemoimmunotherapy (CIT) with oregovomab (anti-CA-125), gemcitabine/leucovorin/fluorouracil for 3 cycles, followed by nelfinavir (1250 mg bid for 5 weeks) and SBRT (40 Gy/5 fractions) during the third week of nelfinavir.
Study: 31513018
Drug: Oregovomab (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oregovomab (2 mg) administered for 7 total doses (3 pre-SBRT, 1 between SBRT and resection, and 3 postoperatively)
Study: 31514508
Drug: Obstructive Sleep
Approvals — FDA: no, EMA: no, PMDA: no
Description: Obstructive Sleep Apnea (OSA) treatment, specific intervention details not available
Study: 31515828
Drug: GHX02 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GHX02 at 0, 1250, 2500, and 5000 mg/kg/day for 28 days
Study: 31516727
Drug: Eccentric exercise
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eccentric exercise plus manual therapy
Study: 31516734
Drug: Eplerenone 50
Normalized name: eplerenone 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eplerenone 50 mg/day for 4 weeks
Study: 31518254
Drug: Photo story
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Photo story in tablet format
Study: 31518254
Drug: Traditional brochure
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Traditional brochure in tablet format
Study: 31519196
Drug: Low-dose chest
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose chest CT (LDCT) and circulating tumor cells (CTC) search on a blood sample, followed by two additional screening rounds at one-year intervals.
Study: 31519676
Drug: Community-based exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Community-based exercise (minimum of 60 min of mild-to-moderate intensity full body exercise twice weekly for a 12-week period)
Study: 31520559
Drug: Aflibercept (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aflibercept (4 mg/kg) plus FOLFIRI every 2 weeks
Study: 31520559
Drug: Pre-dose 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-dose 3 levels of biomarkers
Study: 31521128
Drug: Postoperative adjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative adjuvant chemotherapy (PAC)
Study: 31521134
Drug: 3 cycles
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 cycles of FOLFIRINOX neoadjuvant chemotherapy followed by a short-course of carbon ion radiotherapy (CIRT)
Study: 31521574
Drug: Central augmentation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Central augmentation index
Study: 31523049
Drug: Anticitrullinated protein
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anticitrullinated protein antibody/rheumatoid factor positivity
Study: 31523279
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy (clarithromycin, metronidazole, levofloxacin)